/

Società

En

Non verificato

Enterprise Therapeutics Ltd

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

3 comunicati stampa

Guarda tutti i comunicati

12/05/2026

Eventi

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Enterprise Therapeutics Achieves Primary Efficacy Outcome in Phase 2 Clinical Trial for Cystic Fibrosis With Novel Inhaled ENaC Blocker ETD001

Fonte

Enterprise Therapeutics Ltd

Emittente

1.00

0

09/12/2025

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

Fonte

Enterprise Therapeutics Ltd

Emittente

1.00

0

26/09/2024

Industria

Salute

Igiene alimentare

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Enterprise Therapeutics Granted ‘Rare Pediatric Disease Designation’ in the US for Novel Cystic Fibrosis Investigational Therapy ETD001

Fonte

Enterprise Therapeutics Ltd

Emittente

1.00

0

Seguaci

0

Compatibilità

0